Annual Net Income
-$21.43 M
+$74.14 M+77.58%
31 December 2023
Summary:
Y-mAbs Therapeutics annual net profit is currently -$21.43 million, with the most recent change of +$74.14 million (+77.58%) on 31 December 2023. During the last 3 years, it has risen by +$97.91 million (+82.04%). YMAB annual net income is now -25.62% below its all-time high of -$17.06 million, reached on 31 December 2016.YMAB Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$7.00 M
+$2.25 M+24.34%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly net profit is currently -$7.00 million, with the most recent change of +$2.25 million (+24.34%) on 30 September 2024. Over the past year, it has increased by +$749.00 thousand (+9.67%). YMAB quarterly net income is now -120.94% below its all-time high of $33.41 million, reached on 31 March 2021.YMAB Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$23.86 M
+$749.00 K+3.04%
30 September 2024
Summary:
Y-mAbs Therapeutics TTM net profit is currently -$23.86 million, with the most recent change of +$749.00 thousand (+3.04%) on 30 September 2024. Over the past year, it has dropped by -$4.58 million (-23.76%). YMAB TTM net income is now -523.57% below its all-time high of -$3.83 million, reached on 30 September 2017.YMAB TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +77.6% | +9.7% | -23.8% |
| 3 y3 years | +82.0% | +75.8% | +37.7% |
| 5 y5 years | +50.5% | +70.8% | +66.8% |
YMAB Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +82.0% | -704.8% | +83.0% | -23.8% | +82.3% |
| 5 y | 5 years | at high | +82.0% | -120.9% | +83.0% | -23.8% | +82.3% |
| alltime | all time | -25.6% | +82.0% | -120.9% | +83.0% | -523.6% | +82.3% |
Y-mAbs Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$7.00 M(-24.3%) | -$23.86 M(-3.0%) |
| June 2024 | - | -$9.25 M(+39.5%) | -$24.61 M(+13.6%) |
| Mar 2024 | - | -$6.63 M(+571.0%) | -$21.67 M(+1.1%) |
| Dec 2023 | -$21.43 M(-77.6%) | -$988.00 K(-87.2%) | -$21.43 M(+11.1%) |
| Sept 2023 | - | -$7.75 M(+22.9%) | -$19.28 M(-50.6%) |
| June 2023 | - | -$6.30 M(-1.4%) | -$39.06 M(-47.1%) |
| Mar 2023 | - | -$6.39 M(-652.3%) | -$73.89 M(-22.7%) |
| Dec 2022 | -$95.57 M(+72.9%) | $1.16 M(-104.2%) | -$95.57 M(-28.5%) |
| Sept 2022 | - | -$27.53 M(-33.1%) | -$133.62 M(-1.0%) |
| June 2022 | - | -$41.13 M(+46.5%) | -$134.95 M(+15.6%) |
| Mar 2022 | - | -$28.07 M(-23.9%) | -$116.76 M(+111.2%) |
| Dec 2021 | -$55.27 M(-53.7%) | -$36.89 M(+27.8%) | -$55.27 M(+44.3%) |
| Sept 2021 | - | -$28.86 M(+25.8%) | -$38.31 M(-9.4%) |
| June 2021 | - | -$22.94 M(-168.6%) | -$42.29 M(-29.2%) |
| Mar 2021 | - | $33.41 M(-267.6%) | -$59.74 M(-49.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$119.34 M(+47.3%) | -$19.93 M(-39.3%) | -$119.34 M(-2.6%) |
| Sept 2020 | - | -$32.83 M(-18.7%) | -$122.54 M(+7.8%) |
| June 2020 | - | -$40.39 M(+54.3%) | -$113.63 M(+24.5%) |
| Mar 2020 | - | -$26.18 M(+13.2%) | -$91.27 M(+12.6%) |
| Dec 2019 | -$81.03 M(+87.2%) | -$23.14 M(-3.3%) | -$81.03 M(+12.6%) |
| Sept 2019 | - | -$23.92 M(+32.6%) | -$71.95 M(+21.0%) |
| June 2019 | - | -$18.04 M(+13.2%) | -$59.46 M(+14.9%) |
| Mar 2019 | - | -$15.93 M(+13.3%) | -$51.73 M(+19.5%) |
| Dec 2018 | -$43.27 M(+125.8%) | -$14.06 M(+23.1%) | -$43.27 M(+12.5%) |
| Sept 2018 | - | -$11.43 M(+10.9%) | -$38.47 M(+24.6%) |
| June 2018 | - | -$10.30 M(+37.7%) | -$30.87 M(+50.1%) |
| Mar 2018 | - | -$7.48 M(-19.1%) | -$20.56 M(+57.2%) |
| Dec 2017 | -$19.16 M(+12.3%) | -$9.25 M(+141.8%) | -$13.08 M(+241.8%) |
| Sept 2017 | - | -$3.83 M | -$3.83 M |
| Dec 2016 | -$17.06 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual net profit?
- What is the all time high annual net income for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual net income year-on-year change?
- What is Y-mAbs Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly net income year-on-year change?
- What is Y-mAbs Therapeutics TTM net profit?
- What is the all time high TTM net income for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM net income year-on-year change?
What is Y-mAbs Therapeutics annual net profit?
The current annual net income of YMAB is -$21.43 M
What is the all time high annual net income for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual net profit is -$17.06 M
What is Y-mAbs Therapeutics annual net income year-on-year change?
Over the past year, YMAB annual net profit has changed by +$74.14 M (+77.58%)
What is Y-mAbs Therapeutics quarterly net profit?
The current quarterly net income of YMAB is -$7.00 M
What is the all time high quarterly net income for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly net profit is $33.41 M
What is Y-mAbs Therapeutics quarterly net income year-on-year change?
Over the past year, YMAB quarterly net profit has changed by +$749.00 K (+9.67%)
What is Y-mAbs Therapeutics TTM net profit?
The current TTM net income of YMAB is -$23.86 M
What is the all time high TTM net income for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM net profit is -$3.83 M
What is Y-mAbs Therapeutics TTM net income year-on-year change?
Over the past year, YMAB TTM net profit has changed by -$4.58 M (-23.76%)